Enesi Pharma’s ImplaVax® Solid-Dose Needle-free Vaccination Technology Featured in the Wall Street Journal

Enesi Pharma’s CEO, David Hipkiss, spoke to WSJ reporter Jason Douglas about Enesi’s ImplaVax® solid-dose needle-free vaccination technology as part of a larger feature investigating how the COVID-19 pandemic has spurred innovation into new vaccination technologies that use alternative approaches to traditional needle and syringe delivery.

The story, published on 3rd March 2021, can be accessed at: